Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

24.95 -0.01 (-0.04%)
Streaming Delayed Price Updated: 12:49 PM EDT, Jul 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
What's Going On With ACADIA Pharmaceuticals Stock? ↗
ACADIA Pharmaceuticals shares are trading lower by 4.6% during Tuesday's session. The company appointed Catherine Owen Adams as CEO. 
Via Benzinga
News headline image
Expert Ratings For ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods ↗
Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic. 
Via Benzinga
News headline image
Ryan Reynolds Announces More to Parkinson’s® Campaign
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' ↗
Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. 
Via Investor's Business Daily
Topics Earnings
News headline image
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
From Acadia Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Sorry Pharma Stocks to Sell in May While You Still Can ↗
Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks. 
Via InvestorPlace
News headline image
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar ↗
Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider. 
Via InvestorPlace
News headline image
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗
ACAD stock results show that ACADIA Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.